Axxcess Wealth Management LLC Sells 220 Shares of AstraZeneca PLC (NASDAQ:AZN)

Axxcess Wealth Management LLC lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,826 shares of the company’s stock after selling 220 shares during the period. Axxcess Wealth Management LLC’s holdings in AstraZeneca were worth $1,614,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Lindbrook Capital LLC raised its stake in shares of AstraZeneca by 1.7% during the first quarter. Lindbrook Capital LLC now owns 8,005 shares of the company’s stock valued at $542,000 after acquiring an additional 137 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after acquiring an additional 146 shares in the last quarter. Gallacher Capital Management LLC raised its stake in AstraZeneca by 2.8% in the first quarter. Gallacher Capital Management LLC now owns 5,431 shares of the company’s stock worth $368,000 after buying an additional 150 shares in the last quarter. Beaird Harris Wealth Management LLC raised its stake in AstraZeneca by 8.9% in the fourth quarter. Beaird Harris Wealth Management LLC now owns 1,851 shares of the company’s stock worth $125,000 after buying an additional 151 shares in the last quarter. Finally, Sage Mountain Advisors LLC raised its stake in AstraZeneca by 2.7% in the first quarter. Sage Mountain Advisors LLC now owns 6,017 shares of the company’s stock worth $408,000 after buying an additional 158 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on AZN shares. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. BMO Capital Markets boosted their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Finally, Argus boosted their price objective on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Stock Down 0.5 %

NASDAQ AZN traded down $0.39 on Friday, hitting $78.13. The stock had a trading volume of 5,878,523 shares, compared to its average volume of 3,316,286. The business’s fifty day moving average price is $78.54 and its 200 day moving average price is $71.92. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.89 and a quick ratio of 0.70. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $80.86. The stock has a market cap of $242.25 billion, a price-to-earnings ratio of 38.30, a price-to-earnings-growth ratio of 1.42 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.01. The business had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.66%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.08 earnings per share. Equities research analysts anticipate that AstraZeneca PLC will post 4.03 earnings per share for the current year.

AstraZeneca Cuts Dividend

The business also recently disclosed a Semi-Annual dividend, which will be paid on Monday, September 9th. Stockholders of record on Friday, August 9th will be issued a dividend of $0.49 per share. The ex-dividend date of this dividend is Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is presently 94.61%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.